Euroopa Liit - eesti - EMA (European Medicines Agency)

sfl pharmaceuticals deutschland gmbh - nyxthracis - anthrax - suguhormoonid ja immunoglobuliinid, - obiltoxaximab sfl is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to bacillus anthracis (see section 5. obiltoxaximab sfl is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.

Eesti - eesti - Ravimiamet

baxter holding b.v. - tsiprofloksatsiin - infusioonilahus - 2mg 1ml 50ml 1tk; 2mg 1ml 100ml 1tk; 2mg 1ml 200ml 1tk